| CARLAT PUBLISHING

Low Dose Abilify Ineffective as Adjunct for MDD

Augmentation of antidepressants with antipsychotics has become a common practice, and aripiprazole (Abilify) has been FDA-approved at doses from 2 mg/day to 15 mg/day for this purpose. In a recent report, 225 patients with major depressive disorder (MDD) who had failed one to four antidepressant trials were studied to determine whether low dose Abilify really works. Read More

A 32-year-old pregnant woman with bipolar disorder, well-controlled on valproic acid (Depakote), comes into your office wanting advice on medications. What do you do? Read More

Is Bipolar Disorder Over-Diagnosed?

Whether you work in a hospital or an office setting, you’ve probably seen many patients who come to you with a “history of bipolar disorder.” We’ve seen it, too, in multiple settings at an academic medical center. Is this a new epidemic? Or a redefinition of what it means to be “bipolar”? Read More

How should we diagnose bipolar disorder? It isn’t always easy and current bipolar screening tools are problematic for a number of reasons. Read More

Why should we as psychiatrists focus on the psychosocial aspects of bipolar disorder? Dr. Miklowitz explores the benefits of a treatment program that combines targeted psychosocial treatments and medication. Read More

Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)
Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
READ MORE

General Psychiatry
Using SAMe In Clinical Practice with Garrett Rossi, MD
Read More

General Psychiatry
Psychopharm Commandment #6: MAOIs
MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.
Listen now